Salud financiera de hoja de balance de Nectar Lifesciences
Salud financiera controles de criterios 4/6
Nectar Lifesciences tiene un patrimonio de accionistas total de ₹10.8B y una deuda total de ₹6.3B, lo que sitúa su ratio deuda-patrimonio en 58.4%. Sus activos y pasivos totales son ₹21.8B y ₹11.1B respectivamente. El BAIT de Nectar Lifesciences es de ₹1.0B, por lo que su ratio de cobertura de intereses es de 1.3. Tiene efectivo e inversiones a corto plazo que ascienden a ₹187.3M.
Información clave
58.4%
Ratio deuda-patrimonio
₹6.29b
Deuda
| Ratio de cobertura de intereses | 1.3x |
| Efectivo | ₹187.35m |
| Patrimonio | ₹10.78b |
| Total pasivo | ₹11.05b |
| Activos totales | ₹21.83b |
Actualizaciones recientes sobre salud financiera
Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden
Jul 27
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Dec 22Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?
Jun 16Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jun 21Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jul 29Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet
Jan 21Recent updates
Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive
Oct 11Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth
Aug 22Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden
Jul 27Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Feb 19Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Dec 22Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?
Jun 16Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jun 21Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jul 29Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?
Feb 25Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet
Jan 21Zooming in on NSE:NECLIFE's 0.3% Dividend Yield
Nov 02Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Sep 07
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today
Aug 09The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More
Aug 09What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E
Jul 13Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹13.1B) de NECLIFE superan a sus pasivos a corto plazo (₹10.0B).
Pasivo a largo plazo: Los activos a corto plazo de NECLIFE (₹13.1B) superan a sus pasivos a largo plazo (₹1.1B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de NECLIFE (56.6%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de NECLIFE ha pasado de 78.1% a 58.4% en los últimos 5 años.
Cobertura de la deuda: La deuda de NECLIFE está bien cubierta por el flujo de caja operativo (25.2%).
Cobertura de intereses: Los pagos de intereses de la deuda de NECLIFE no están bien cubiertos por el BAIT (1.3x cobertura).